MA52906A - Procédé de préparation d'amg 416 - Google Patents

Procédé de préparation d'amg 416

Info

Publication number: MA52906A
Authority: MA; Morocco
Prior art keywords: amg; preparation process; preparation
Prior art date: 2014-04-03

Application number

MA052906A

Other languages

English (en)

Inventor

Jeroen Bezemer

Ying Chen

Richard Crockett

Kevin Crossley

Sheng Cui

Liang Huang

Sian Jones

Asher Lower

Krishnakumar Ranganathan

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-03

Filing date

2015-04-03

Publication date

2021-04-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54241346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52906(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-03 Application filed by Amgen Inc filed Critical Amgen Inc

2021-04-21 Publication of MA52906A publication Critical patent/MA52906A/fr

Links

ANIAZGVDEUQPRI-ZJQCGQFWSA-N etelcalcetide Chemical compound NC(N)=NCCC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O ANIAZGVDEUQPRI-ZJQCGQFWSA-N 0.000 title 1
229950006502 etelcalcetide Drugs 0.000 title 1
108091022127 etelcalcetide hydrochloride Proteins 0.000 title 1
238000002360 preparation method Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Glass Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MA052906A 2014-04-03 2015-04-03 Procédé de préparation d'amg 416 MA52906A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201461974899P	2014-04-03	2014-04-03

Publications (1)

Publication Number	Publication Date
MA52906A true MA52906A (fr)	2021-04-21

Family

ID=54241346

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA39628A MA39628B1 (fr)	2014-04-03	2015-04-03	Procédé de préparation d'amg 416
MA052906A MA52906A (fr)	2014-04-03	2015-04-03	Procédé de préparation d'amg 416

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA39628A MA39628B1 (fr)	2014-04-03	2015-04-03	Procédé de préparation d'amg 416

Country Status (27)

Country	Link
US (3)	US10407464B2 (fr)
EP (3)	EP3126373B1 (fr)
JP (1)	JP6710158B2 (fr)
KR (1)	KR102397271B1 (fr)
CN (3)	CN119874825A (fr)
AU (1)	AU2015240527B2 (fr)
CA (1)	CA2944194C (fr)
CL (1)	CL2016002513A1 (fr)
CY (1)	CY1123100T1 (fr)
DK (1)	DK3126373T3 (fr)
EA (1)	EA032597B1 (fr)
ES (2)	ES2786225T3 (fr)
HR (1)	HRP20200527T1 (fr)
HU (1)	HUE048489T2 (fr)
IL (1)	IL248059B2 (fr)
LT (1)	LT3126373T (fr)
MA (2)	MA39628B1 (fr)
ME (1)	ME03781B (fr)
MX (1)	MX374205B (fr)
PL (1)	PL3126373T3 (fr)
PT (1)	PT3126373T (fr)
RS (1)	RS60187B1 (fr)
SG (1)	SG11201608176VA (fr)
SI (1)	SI3126373T1 (fr)
SM (1)	SMT202000207T1 (fr)
WO (1)	WO2015154031A1 (fr)
ZA (1)	ZA201606844B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2916222C (fr)	2013-06-28	2021-05-18	Amgen Inc.	Formulation liquide stable d'amg 416 (etelcalcetide)
PL3126373T3 (pl)	2014-04-03	2020-07-27	Amgen Inc.	Sposób wytwarzania amg 416
CN106928320B (zh) *	2015-12-31	2021-01-15	深圳翰宇药业股份有限公司	一种合成Etelcalcetide的方法
CN106928321B (zh) *	2015-12-31	2019-07-26	深圳翰宇药业股份有限公司	一种合成Etelcalcetide的方法
WO2017162650A1 (fr)	2016-03-23	2017-09-28	Bachem Holding Ag	Procédé de préparation de peptides de type glucagon
US10858390B2 (en) *	2016-09-02	2020-12-08	Cem Corporation	Use of excess carbodiimide for peptide synthesis at elevated temperatures
CN108101959B (zh) *	2016-11-24	2021-07-09	四川科伦药物研究院有限公司	一种制备高纯度多肽或其类似物的方法
CN106928171B (zh) *	2017-05-03	2019-08-13	成都郑源生化科技有限公司	Fmoc-Arg（Pbf）-OH的合成方法
TW201915009A (zh) *	2017-10-03	2019-04-16	中化合成生技股份有限公司	合成依特卡肽（Ｅｔｅｌｃａｌｃｅｔｉｄｅ）或其鹽類之方法
CN110498835B (zh) *	2018-05-17	2021-06-08	深圳翰宇药业股份有限公司	一种合成etelcalcetide的方法
CN109280078B (zh) *	2018-10-30	2019-06-25	成都诺和晟泰生物科技有限公司	一种制备维拉卡肽的方法
CN112062811B (zh) *	2019-06-10	2022-03-25	深圳翰宇药业股份有限公司	一种维拉卡肽的合成方法
WO2021038431A1 (fr)	2019-08-26	2021-03-04	Auro Peptides Ltd	Procédé amélioré pour la préparation de chlorhydrate d'ételcalcétide
EP3875466A1 (fr) *	2020-03-05	2021-09-08	Fresenius Kabi iPSUM S.r.l.	Procédé de synthèse de l'ételcalcétide
JP7766028B2 (ja)	2020-06-03	2025-11-07	中外製薬株式会社	高難度配列の効率的ペプチド縮合法
CN111925415A (zh) *	2020-08-10	2020-11-13	海南中和药业股份有限公司	一种维拉卡肽杂质的制备方法
TWI792442B (zh)	2021-07-23	2023-02-11	建誼生技股份有限公司	依特卡肽鹽酸鹽之製造方法
CN114524860B (zh) *	2021-12-29	2025-01-24	深圳翰宇药业股份有限公司	一种Etelcalcetide的合成方法及其应用
CN120699096B (zh) *	2025-07-07	2026-01-23	苏州天马医药集团天吉生物制药有限公司	一种依特卡肽的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3941763A (en)	1975-03-28	1976-03-02	American Home Products Corporation	PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
EP0339695A3 (fr)	1988-04-29	1990-05-30	Stichting Voor De Technische Wetenschappen	Procédé de préparation d'un conjugué antigénique ou immunogénique ainsi que l'utilisation de tels conjugués
SE9603465D0 (sv)	1996-09-23	1996-09-23	Astra Ab	New compounds
NO311807B1 (no) *	1999-03-04	2002-01-28	Bionor Immuno As	HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
EP2205624B1 (fr)	2007-10-27	2016-09-07	Corden Pharma Colorado, Inc.	Synthèse de peptides insulinotropes à l'aide de techniques hybrides utilisant une phase solide et une phase en solution
CN101250172B (zh)	2008-03-07	2012-05-02	上海瀚鸿化工科技有限公司	精氨酸双保护制备工艺
US8742028B2 (en)	2009-05-06	2014-06-03	Mallinckrodt Llc	Solid support for Fmoc-solid phase synthesis of peptide acids
ES2729051T3 (es)	2009-07-29	2019-10-30	Kai Pharmaceuticals Inc	Agentes terapéuticos para reducir los niveles de hormona paratiroidea
EP2560491A1 (fr) *	2010-04-21	2013-02-27	Signature Therapeutics, Inc.	Agonistes opiacés périphériques et antagonistes opiacés périphériques
US20140024592A1 (en) *	2010-09-08	2014-01-23	Howard Florey Institute Of Experimental Physiology And Medicine	Modified Relaxin Polypeptides
WO2013042129A1 (fr)	2011-09-23	2013-03-28	Natco Pharma Limited	Procédé amélioré pour la préparation de bivalirudine
CA2916222C (fr)	2013-06-28	2021-05-18	Amgen Inc.	Formulation liquide stable d'amg 416 (etelcalcetide)
PL3126373T3 (pl)	2014-04-03	2020-07-27	Amgen Inc.	Sposób wytwarzania amg 416
CN105504012A (zh) *	2014-09-30	2016-04-20	深圳翰宇药业股份有限公司	一种多肽的制备方法
CN107434820A (zh) *	2017-08-07	2017-12-05	南京工业大学	一种维拉卡肽的合成方法

2015
- 2015-04-03 PL PL15773570T patent/PL3126373T3/pl unknown
- 2015-04-03 MA MA39628A patent/MA39628B1/fr unknown
- 2015-04-03 IL IL248059A patent/IL248059B2/en unknown
- 2015-04-03 MX MX2016012965A patent/MX374205B/es active IP Right Grant
- 2015-04-03 CN CN202510112970.9A patent/CN119874825A/zh active Pending
- 2015-04-03 WO PCT/US2015/024347 patent/WO2015154031A1/fr not_active Ceased
- 2015-04-03 MA MA052906A patent/MA52906A/fr unknown
- 2015-04-03 US US15/300,209 patent/US10407464B2/en active Active
- 2015-04-03 LT LTEP15773570.5T patent/LT3126373T/lt unknown
- 2015-04-03 ES ES15773570T patent/ES2786225T3/es active Active
- 2015-04-03 SM SM20200207T patent/SMT202000207T1/it unknown
- 2015-04-03 RS RS20200448A patent/RS60187B1/sr unknown
- 2015-04-03 ES ES20160369T patent/ES2943671T3/es active Active
- 2015-04-03 DK DK15773570.5T patent/DK3126373T3/da active
- 2015-04-03 CA CA2944194A patent/CA2944194C/fr active Active
- 2015-04-03 HR HRP20200527TT patent/HRP20200527T1/hr unknown
- 2015-04-03 ME MEP-2020-83A patent/ME03781B/fr unknown
- 2015-04-03 CN CN202510112966.2A patent/CN119899242A/zh active Pending
- 2015-04-03 AU AU2015240527A patent/AU2015240527B2/en active Active
- 2015-04-03 KR KR1020167030590A patent/KR102397271B1/ko active Active
- 2015-04-03 CN CN201580029560.2A patent/CN106795201A/zh active Pending
- 2015-04-03 SG SG11201608176VA patent/SG11201608176VA/en unknown
- 2015-04-03 JP JP2016560462A patent/JP6710158B2/ja active Active
- 2015-04-03 SI SI201531173T patent/SI3126373T1/sl unknown
- 2015-04-03 EP EP15773570.5A patent/EP3126373B1/fr active Active
- 2015-04-03 PT PT157735705T patent/PT3126373T/pt unknown
- 2015-04-03 EP EP20160369.3A patent/EP3708576B1/fr active Active
- 2015-04-03 EA EA201692001A patent/EA032597B1/ru not_active IP Right Cessation
- 2015-04-03 EP EP23150870.6A patent/EP4219526A3/fr not_active Withdrawn
- 2015-04-03 HU HUE15773570A patent/HUE048489T2/hu unknown
2016
- 2016-10-03 CL CL2016002513A patent/CL2016002513A1/es unknown
- 2016-10-05 ZA ZA2016/06844A patent/ZA201606844B/en unknown
2019
- 2019-08-05 US US16/532,344 patent/US11377474B2/en active Active
2020
- 2020-04-29 CY CY20201100391T patent/CY1123100T1/el unknown
2022
- 2022-06-28 US US17/852,263 patent/US20230099078A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN119899242A (zh)	2025-04-29
IL248059B2 (en)	2023-10-01
DK3126373T3 (da)	2020-05-04
BR112016022868A2 (pt)	2018-07-03
WO2015154031A1 (fr)	2015-10-08
JP2017511332A (ja)	2017-04-20
IL248059B1 (en)	2023-06-01
LT3126373T (lt)	2020-05-11
ES2943671T3 (es)	2023-06-15
US20170190739A1 (en)	2017-07-06
US10407464B2 (en)	2019-09-10
CN106795201A (zh)	2017-05-31
SI3126373T1 (sl)	2020-06-30
MA39628B1 (fr)	2020-05-29
ME03781B (fr)	2021-04-20
MX2016012965A (es)	2017-07-06
AU2015240527B2 (en)	2019-09-26
PL3126373T3 (pl)	2020-07-27
CN119874825A (zh)	2025-04-25
IL248059A0 (en)	2016-11-30
US20230099078A1 (en)	2023-03-30
HUE048489T2 (hu)	2020-07-28
JP6710158B2 (ja)	2020-06-17
AU2015240527A1 (en)	2016-10-20
SMT202000207T1 (it)	2020-05-08
EP3708576B1 (fr)	2023-02-22
ZA201606844B (en)	2018-07-25
EP3708576A1 (fr)	2020-09-16
CY1123100T1 (el)	2021-10-29
US11377474B2 (en)	2022-07-05
ES2786225T3 (es)	2020-10-09
CA2944194C (fr)	2022-04-19
KR102397271B1 (ko)	2022-05-16
US20190352336A1 (en)	2019-11-21
PT3126373T (pt)	2020-04-24
KR20170026326A (ko)	2017-03-08
EP3126373B1 (fr)	2020-03-04
CA2944194A1 (fr)	2015-10-08
CL2016002513A1 (es)	2018-03-23
RS60187B1 (sr)	2020-06-30
EP4219526A3 (fr)	2023-08-30
EA032597B1 (ru)	2019-06-28
EP3126373A1 (fr)	2017-02-08
EP3126373A4 (fr)	2018-06-20
HRP20200527T1 (hr)	2020-06-26
EA201692001A1 (ru)	2017-02-28
SG11201608176VA (en)	2016-10-28
EP4219526A2 (fr)	2023-08-02
MX374205B (es)	2025-03-05

Publication	Publication Date	Title
MA52906A (fr)	2021-04-21	Procédé de préparation d'amg 416
EP4036099C0 (fr)	2025-03-19	Méthodes pour la préparation de ribosides
HUE059158T2 (hu)	2022-10-28	Eljárás pridopidin elõállítására
EP3398960A4 (fr)	2019-08-14	Procédé de préparation du sermaglutide
EP3302794A4 (fr)	2019-06-26	Procédé d'époxydation
HUE064612T2 (hu)	2024-04-28	Eljárás brivaracetam elõállítására
EP3209720C0 (fr)	2023-06-14	Procédé de polymérisation en solution en continu
EP3392266A4 (fr)	2019-08-14	Procédé de synthèse de linaclotide
HUE050974T2 (hu)	2021-01-28	Eljárás pirimidinszulfamid-származékok elõállítására
HUE058257T2 (hu)	2022-07-28	Eljárások oxatiazin-jellegû vegyületek elõállítására
IL254894A0 (en)	2017-12-31	A process for the preparation of dicycloplatin
EP3398957A4 (fr)	2019-08-14	Procédé de synthèse de l'ételcalcétide
EP2977448A4 (fr)	2016-11-09	Procédé de préparation de chondrocytes
EP2970037A4 (fr)	2016-10-26	Procédés de préparation d'alkylfurannes
HUE049170T2 (hu)	2020-09-28	Eljárás szubsztituált cikloszerinek elõállítására
EP3341359A4 (fr)	2019-04-24	Procédé de préparation d'aprémilast
EP3372596A4 (fr)	2019-05-08	Procédé de préparation de tédizolide, intermédiaire de tédizolide et procédé pour sa préparation
MA42423A (fr)	2018-05-23	Procédé de préparation d'un revêtement
FR3038312B1 (fr)	2017-06-23	Procede de preparation de polyols
HUE047756T2 (hu)	2020-05-28	Eljárás metil-merkaptán elõállítására
EP2910542A4 (fr)	2016-09-28	Procédé de préparation de méthylolalcanal
EP3265100A4 (fr)	2019-01-09	Procédés de préparation de fluorokétolides
EP3647304A4 (fr)	2021-03-17	Procédé de préparation de 2-fluoroacrylate
FR3022234B1 (fr)	2017-10-20	Procede de preparation de nanofils de silicium.
FR3019967B1 (fr)	2017-04-28	Procede d'ostreiculture ameliore